Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Molecular Adds to Management; Douglas Liu Joins Qiagen from Bayer; Trevor Hawkins Becomes Director of Tm Bioscience; Eric Jakobsson Resigns from NIGMS Center for Bioinformatics; and Others

CombiMatrix Molecular Diagnostics has added three people to its management team, the company's parent, Acacia Research, said yesterday.

 

Matthew Moore has become director of research and development. He joins CMD from US LABS, where he was part of the research and development team. Mooreholds a PhD from the Universityof New South Wales in Australia.

 

Robert Embree has become director of laboratory operations. Previously, he was managing director of global immunohistochemistry and virtual image analysis of US LABS. He holds a BS from the University of Redlands in Southern California.

 

John Besser has joined CMD as chief financial officer. He comes to CMD from the Quest Diagnostics Nichols Institute, where he served as controller. Besser holds a BS in business management from the Universityof Utah.


 

Sigma-Aldrich announced several internal management changes yesterday in connection with its recent reorganization.

 

Shaf Yousaf, vice president of corporate R&D and biotechnology marketing, will become president of the firm's new Biotech unit.

 

David Julien, most recently president of Sigma's biotechnology business, was named president of the new Specialties unit.

 

Gilles Cottier, vice president of sales at Sigma, was appointed president of the new Essentials unit.

 

The firm's SAFC business unit will continue to be led by Frank Wicks, who has served as its president since January 2003.


 

Douglas Liu has joined Qiagen as vice president of global operations, the company said yesterday. He will also serve on the firm's executive committee and will be based at Qiagen's headquarters in Hilden, Germany. Liu comes to Qiagen from Bayer Healthcare, where he was head of operations for nucleic acid diagnostics in the USand worked in strategic planning and consulting at Bayer's headquarters in Germany. Liu holds an MBA from BostonUniversity and a BS from the Universityof Illinois.


 

Steve Noblitt has been promoted to US sales manager of Nonlinear USA, the USsubsidiary of Nonlinear Dynamics, the company said yesterday. For the past four years, he was Nonlinear's Midwestsales manager. Prior to that, he worked as a field applications specialist for Molecular Dynamics and Amersham Pharmacia Biotech.


 

James Vincent has been appointed as director of Alnylam Pharmaceuticals, the company said today. He used to be chief excecutive officer and chairman of Biogen and currently serves on the board of trustees for DukeUniversity.


 

Trevor Hawkins has joined the board of directors of Tm Bioscience, replacing Geoffrey Beattie, the company said yesterday. He is the chief science and technology officer of MDS. Prior to that, he was president of the molecular diagnostics business unit of GE Healthcare. Previously, he was senior vice president of development and new business initiatives and senior vice president of genomics at Amersham Biosciences. Hawkins holds a bachelor of science from the Universityof Sussex and a PhD in biochemistry from the Universityof Sussexand MCR Laboratory of Molecular Biology in Cambridge, UK.


 

John Wareham, who retired from his position as chairman and CEO of Beckman Coulter in February, entered into a retirement and consulting agreement with the company on June 30, according to an SEC filing last week. Warehamwill serve as a consultant for three years.


 

Tim Tasker has been appointed as executive vice president of clinical development and a member of the executive committee of Evotec, the Hamburg, Germany-based drug-discovery firm said last week. Tasker most recently served as vice president of global clinical units, clinical pharmacology, and discovery medicine at GlaxoSmithKline. He holds an MD from LondonUniversity and a BA in physiological sciences from the Universityof Oxford.


 

Nassim Usman has been named entrepreneur-in-residence, focusing on investment opportunities in biotechnology, at Morgenthaler Ventures. Previously, he was senior vice president and COO of Sirna Therapeutics. Prior to that, he was CSO at Sirna, as well as its previous incarnation, Ribozyme Pharmaceuticals. He has also served on the board of directors at Archemix and Atugen. Usman holds a BSc and PhD in chemistry from McGillUniversity.


 

John Mendlein has become the chief executive officer of Compound Therapeutics of Waltham, Mass., GenomeWeb News has learned. He is the former CEO of Integrative Proteomics.


 

Paul Blake has been elected to the board of directors of ViaCell, the Boston-based company said on Monday. Blake is executive vice president for worldwide clinical research and regulatory affairs at Cephalon. Prior to that, he was chief medical officer of MDS Proteomics. Blake holds a medical degree from LondonUniversity.


 

Eric Jakobssonhas resigned from his position as director of the Center for Bioinformatics and Computational Biology at the National Institute of General Medical Sciences and the Chair of the Biomedical Information Science and Technology Initiative Consortium at the National Institutes of Health, BioInform, a GenomeWeb newsletter, reported this week. NIH has posted a vacancy announcement for the position on its website, and a member of the NIGMS human resources staff confirmed that Jakobsson has resigned. Jakobsson joined NIGMS in 2003 as the first director of the CBCB. Prior to that, he was a professor in the Department of Molecular and Integrative Physiology and director of the Center for Biophysics and Computational Biology at the University of Illinois at Urbana-Champaign.


 

Ronald Evans, professor and head of the Gene Expression Laboratory of the Salk Institute for Biological Studies, will receive the 2005 Grande Médaille D'Or at the French Academy of Sciences in Parisfor his research into hormones, the Salk Institute said yesterday. He will receive the award, France's highest scientific honor, on Nov. 15. Evans is also an investigator of the Howard Hughes Medical Institute. Last year, he won the Lasker Award for Basic Medical Research. Evans holds a PhD in microbiology and immunology and a BA in bacteriology from the University of California Los Angeles.


 

Bruce Bistrian has become president of the Federation of American Societies for Experimental Biology. He is chief of clinical nutrition at Beth Israel Deaconess Medical Center and professor of medicine at Harvard Medical School. He will lead FASEB, a coalition of 23 members societies representing more than 65,000 biomedical researchers, for one year. Bistrian holds a medical degree from CornellUniversity, an MPH degree from Johns Hopkins University, and a PhD in nutritional biochemistry and metabolism from MIT.


 

Thomas McLain has been appointed to the board of directors of the Biotechnology Industry Organization. He is one of 11 new board members, who will each serve two-year terms. McLain is currently the chairman, CEO and president of Nabi Pharmaceuticals.


 

Promoted? Changing jobs?GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.